Nov. 2023 Investor Letter: Further, we were able
Post# of 148278
(Total Views: 653)
Posted On: 03/21/2024 9:40:15 AM
Nov. 2023 Investor Letter:
Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, not with standing other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come."
Q&A:
"For example, KOLs consulting with the Company identified a clinical trial in the HIV space they feel strongly about that will help patients and can be conducted in a time- and cost-effective manner."
__________
Then entered @ Interim & CEO --- Dr. J.
The fruits of their work, we will reap. Science news is coming bubba!! : )
Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, not with standing other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come."
Q&A:
"For example, KOLs consulting with the Company identified a clinical trial in the HIV space they feel strongly about that will help patients and can be conducted in a time- and cost-effective manner."
__________
Then entered @ Interim & CEO --- Dr. J.
The fruits of their work, we will reap. Science news is coming bubba!! : )
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼